AZO heads into its fiscal Q3 results on May 26 carrying a month's worth of short interest growth, a muted but rising put/call ratio, and a stock that has shed over 6% in the past month to $3,347.
The most interesting tension this week is the setup into earnings. Short interest has climbed roughly 15% over the past month to about 2.1% of the free float — a low absolute level, but the direction of travel matters. The bulk of that move happened in late April, when shares outstanding on loan jumped from around 300,000 to above 344,000 in the span of a few days. That build has since plateaued, with short interest essentially flat week-on-week. The borrow market itself is not flashing any stress signals: cost to borrow has actually eased to just 0.36% from 0.41% a month ago, and availability remains extraordinarily loose at over 8,000% — meaning there are roughly 80 shares available to borrow for every one currently lent out. The ORTEX short score of 30.7 is well below the midpoint of its 0-100 range and has drifted lower for two weeks. Positioning looks cautious rather than aggressive — shorts are edging in, but there is no squeeze risk and no meaningful borrow squeeze visible.
Options traders have turned slightly more defensive over the past two weeks, though the move is modest. The put/call ratio has drifted up from below 0.60 in late April to 0.67 now, pulling back toward its 20-day average of 0.67. The z-score is essentially flat. For context, the 52-week high on the PCR reached 1.08, so current readings remain comfortably in neutral territory. RSI sits at about 39.6 — oversold by some definitions — though the stock has not seen a sharp technical reversal yet. Peer , the closest correlated name at 82% correlation, was essentially flat on the week, while dropped nearly 6%. AZO's 1.8% weekly decline falls between those bookends.
The Street is cautiously constructive but has been trimming its ambitions. All analyst changes in the snapshot date from early-to-mid March, following the most recent quarterly report, and consensus sits at hold based on recent data. Most active firms maintained positive ratings but trimmed or barely lifted targets after the Q2 print: TD Cowen cut to $4,250, BMO and Evercore both pulled targets back to the $4,100–$4,300 range. On the other side, Oppenheimer nudged its target up to $4,300 and Argus upgraded to Buy with a $4,325 target. Morgan Stanley, maintaining Overweight, moved its target modestly higher to $4,020. The mean implied upside from current prices is around 26%, which accounts for the stock's slide since those notes were filed. On valuation, the trailing P/E runs near 21x — down about 1.8 points over the past month as earnings estimates held firmer than the stock — and EV/EBITDA sits near 14.9x. Neither multiple looks stretched relative to the company's history, though the bull case rests on tariff pass-through and commercial sales momentum while bears flag the risk of demand softening if consumer spending deteriorates.
Insider activity over the 90-day window is net positive in a nominal sense — the net share position is just under 9,200 shares bought versus sold — but that headline figure is somewhat misleading. The largest single move was CFO Jamere Jackson buying 55 shares at roughly $3,414 in December, alongside smaller purchases from two independent directors. Against those, Senior Vice President Richard Craig Smith sold nearly 9,100 shares in January at prices between $3,500 and $3,700, generating over $33 million in proceeds. The director-level buying looks like program-driven purchases at lower prices; it does not signal a strong conviction call from the top of the management structure.
The earnings history in the snapshot points to consistent post-report selling pressure. The two most recent quarters produced day-one declines of 3.0% and 4.3%, with five-day moves of -9.8% and -4.0% respectively. Those reactions followed a period when the stock traded materially above current levels. With AZO now near $3,347 — close to where some directors were buying in December — the question going into the May 26 print is whether softer same-store sales expectations and tariff headwinds are already in the price, or whether the Street's still-elevated price targets leave room for another round of downward revisions.
See the live data behind this article on ORTEX.
Open AZO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
